1. A method for treating graft immune diseases (chronic GVHD), ulcerative colitis, systemic lupus erythematodes, myasthenia gravis, systemic progressive scleroderma, rheumatoid arthritis, interstitial cystitis, Hashimoto’s diseases, Basedow’s diseases, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, Goodpasture’s syndrome, atrophic gastritis, pernicious anemia, Addison diseases, pemphigus, pemphigoid, lenticular uveitis, sympathetic ophthalmia, primary biliary cirrhosis, active chronic hepatitis, Sjogren’s syndrome, multiple myositis, dermatomyositis, polyarteritis nodosa, rheumatic fever, glomerular nephritis, lupus nephritis, IgA nephtopathy, allergic encephalitis, atopic allergic diseases, bronchial asthma, airway inflammation, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, pollinosis, urticaria, food allergy, Omenn’s syndrome, vernal conjunctivitis or hypereosinophilic syndrome comprising inhibiting the differentiation from Th0 cells to Th2 cells by administering to a patient in need thereof a compound represented by Formula (I):
wherein each of ring A and ring B is independently an optionally substituted benzene ring;
ring C is an optionally substituted pyridine ring wherein the substituent is halogen; hydroxy; lower alkyl which may be substituted by hydroxy or acyloxy; lower alkoxy which may be substituted by halogen, aryl or a 5- or 6-membered heterocyclic group; lower alkenyl; lower alkenyloxy; lower alkynyl; lower alkynyloxy; acyloxy; carboxy; lower alkoxycarbonyl; mercapto; lower alkylthio; lower alkenylthio; amino which may be mono- or di-substituted by halogen, optionally substituted lower alkyl (a substituent is cycloalkyl or a 5- or 6-membered heterocyclic group), optionally halogen-substituted acyl, lower alkenyl, cycloalkyl or lower alkylsulfonyl; imino which may be substituted by lower alkylsulfonyl; hydrazino which may be substituted by lower alkyl, lower alkenyl, optionally substituted lower alkylidene or cycloalkylidene; aminooxy which may be substituted by lower alkyl, lower alkenyl, optionally substituted lower alkylidene or cycloalkylidene; nitro; lower alkylsulfonyl; aryl; a 5- or 6-membered heterocyclic group; oxo; or oxide;
X is \u2014O\u2014, \u2014NR1\u2014 (wherein R1 is hydrogen, optionally substituted lower alkyl, lower alkenyl or lower alkylcarbonyl) or \u2014S(O)-p-wherein p is an integer of 0 to 2;
Y is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted lower alkoxycarbonyl, optionally substituted sulfamoyl, optionally substituted amino, optionally substituted aryl, pyrrole, imidazole, pyrazole, pyridine, pyridazine, pyrimidine, pyrazine, triazole, triazine, isoxazole, oxazole, oxadiazole, isothiazole, thiazole, thiadiazole, furan, thiophene, tetrahydropyran, dihydropyridine, dihydropyridazine, dihydropyrazine, dioxane, oxathiolane, thiane, pyrrolidine, pyrroline, imidazolidine, imidazoline, pyrazolidine, pyrazoline, piperidine, or morpholine;
R1 and Y taken together may form \u2014(CH2)m\u2014, \u2014(CH2)2\u2014T\u2014(CH2)2\u2014 wherein T is O, S or NR\u2032, \u2014CR\u2032\u2550CH\u2014CH\u2550CR\u2032\u2014, \u2014CH\u2550N\u2014CH\u2550CH\u2014, \u2014N\u2550CH\u2014N\u2550CH\u2014, \u2014C (\u2550O)\u2014O\u2014(CH2)r-, \u2014C (\u2550O)\u2014NR\u2032\u2014(CH2)r- or \u2014C(\u2550O)\u2014NR\u2032\u2014N\u2550CH\u2014 wherein m is 4 or 5, r is 2 or 3 and R\u2032 is hydrogen, lower alkyl or lower alkenyl;
Y may be halogen when X is \u2014NR1\u2014 and
Y may be optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl when X is \u2014O\u2014 or \u2014NR1\u2014;
both V1 and V2 are single bonds or one of V1 and V2 is a single bond and the other is \u2014O\u2014, \u2014NH\u2014, \u2014OCH2\u2014, \u2014CH2O\u2014, \u2014CH\u2550CH\u2014, \u2014C\u2261C\u2014, CH(OR2)\u2014 wherein R2 is hydrogen or lower alkyl, \u2014CO\u2014, \u2014NHCHR3\u2014 or CHR3NH\u2014 wherein R3 is hydrogen or hydroxy, or a prodrug, pharmaceutically acceptable salt or solvate thereof.
2. The method as claimed in claim 1 wherein X is \u2014O\u2014 or \u2014NR1\u2014, wherein R1 is hydrogen, lower alkyl or lower alkenyl.
3. The method as claimed in claim 1 wherein Y is optionally substituted lower alkyl or optionally substituted lower alkenyl.
4. The method as claimed in claim 1 wherein both of V1 and V2 are single bonds.
5. The method as claimed in claim 1, wherein the disease is selected from the group consisting of ulcerative colitis, systemic lupus erythematodes, lupus nephritis and rheumatoid arthritis.
6. A method for treating graft immune diseases (chronic GVHD), ulcerative colitis, systemic lupus erythematodes, myasthenia gravis, systemic progressive scleroderma, rheumatoid arthritis, interstitial cystitis, Hashimoto’s diseases, Basedow’s diseases, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, Goodpasture’s syndrome, atrophic gastritis, pernicious anemia, Addison diseases, pemphigus, pemphigoid, lenticular uveitis, sympathetic ophthalmia, primary biliary cirrhosis, active chronic hepatitis, Sjogren’s syndrome, multiple myositis, dermatomyositis, polyarteritis nodosa, rheumatic fever, glomerular nephritis, lupus nephritis, IgA nephtopathy, allergic encephalitis, atopic allergic diseases, bronchial asthma, airway inflammation, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, pollinosis, urticaria, food allergy, Omenn’s syndrome, vernal conjunctivitis or hypereosinophilic syndrome comprising inhibiting the differentiation from Th0 cells to Th2 cells by administering to a patient in need thereof a compound represented by Formula (Ib):
wherein ring C is
and the pyridine ring may be optionally substituted, each of R4, R5, R6, R7, R8, R9, R10, and R11 is independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, carboxy or lower alkoxycarbonyl;
each of X1 and X2 is independently \u2014O\u2014, \u2014CH2\u2014 or \u2014NH\u2014;
each of Y1 and Y2 is independently optionally substituted lower alkyl, optionally substituted arylalkyl or optionally substituted lower alkenyl,
or a prodrug, pharmaceutically acceptable salt or solvate thereof.
7. The method as claimed in claim 6 wherein one of R4 and R5 is hydrogen, hydroxy or lower alkyl and the other is hydrogen or halogen, and both of R6 and R7 are hydrogens.
8. The method as claimed in claim 6 wherein each of R8 and R11 is independently hydrogen, hydroxy, lower alkyl or lower alkoxycarbonyl, and each of R9 and R10 is independently hydroxy, lower alkyl, lower alkoxy or lower alkoxycarbonyl.
9. The method as claimed in claim 6 wherein one of X1 and X2 is \u2014O\u2014 and the other is \u2014NH\u2014.
10. The method as claimed in claim 6 wherein each of Y1 and Y2 is independently optionally halogen-substituted lower alkyl or optionally halogen-substituted lower alkenyl.
11. The method as claimed in claim 6 wherein one of \u2014X\u2032\u2014Y\u2032 and \u2014X2\u2014Y2 is prenylamino and the other is prenyloxy.
12. A method for treating graft immune diseases (chronic GVHD), ulcerative colitis, systemic lupus erythematodes, myasthenia gravis, systemic progressive scleroderma, rheumatoid arthritis, interstitial cystitis, Hashimoto’s diseases, Basedow’s diseases, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, Goodpasture’s syndrome, atrophic gastritis, pernicious anemia, Addison diseases, pemphigus, pemphigoid, lenticular uveitis, sympathetic ophthalmia, primary biliary cirrhosis, active chronic hepatitis, Sjogren’s syndrome, multiple myositis, dermatomyositis, polyarteritis nodosa, rheumatic fever, glomerular nephritis, lupus nephritis, IgA nephtopathy, allergic encephalitis, atopic allergic diseases, bronchial asthma, airway inflammation, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, pollinosis, urticaria, food allergy, Omenn’s syndrome, vernal conjunctivitis or hypereosinophilic syndrome comprising inhibiting the differentiation from Th0 cells to Th2 cells by administering to a patient in need thereof a compound represented by Formula (Ic):
wherein each of ring A and ring B is independently an optionally substituted benzene ring;
ring C is an optionally substituted pyridine ring;
X1 is \u2014O\u2014, \u2014CH2\u2014, or \u2014NH\u2014 and Y1 is optionally substituted lower alkyl, optionally substituted arylalkyl or optionally substituted lower alkenyl;
X3 is \u2014O\u2014 or \u2014NH\u2014;
each of Ra and Rb is independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted acyl, optionally substituted lower alkoxycarbonyl or optionally substituted lower alkylsulfonyl, or they are taken together to form RcRdC\u2550 or \u2014(CReRf)s-;
each of Rc and Rd is independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy, optionally substituted lower alkylthio, optionally substituted lower alkenyloxy, optionally substituted lower alkynyloxy, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted 5- or 6-membered heterocyclyl or they are taken together with a carbon atom to which they are attached to form optionally substituted cycloalkylidene;
each Re is independently hydrogen, lower alkyl, lower alkoxy or amino, and each Rf is independently hydrogen, lower alkyl, lower alkoxy or amino;
n is an integer of 0 to 2 and s is an integer of 2 to 6, or a prodrug, pharmaceutically acceptable salt or solvate thereof.
13. A method for inhibiting the differentiation from Th0 cells to Th2 cells comprising administering to a patient in need thereof a compound represented by Formula (I):
wherein each of ring A and ring B is independently an optionally substituted benzene ring;
ring C is an optionally substituted pyridine ring wherein the substituent is halogen; hydroxy; lower alkyl which may be substituted by hydroxy or acyloxy; lower alkoxy which may be substituted by halogen, aryl or a 5- or 6-membered heterocyclic group; lower alkenyl; lower alkenyloxy; lower alkynyl; lower alkynyloxy; acyloxy; carboxy; lower alkoxycarbonyl; mercapto; lower alkylthio; lower alkenylthio; amino which may be mono- or di-substituted by halogen, optionally substituted lower alkyl (a substituent is cycloalkyl or a 5- or 6-membered heterocyclic group), optionally halogen-substituted acyl, lower alkenyl, cycloalkyl or lower alkylsulfonyl; imino which may be substituted by lower alkylsulfonyl; hydrazino which may be substituted by lower alkyl, lower alkenyl, optionally substituted lower alkylidene or cycloalkylidene; aminooxy which may be substituted by lower alkyl, lower alkenyl, optionally substituted lower alkylidene or cycloalkylidene; nitro; lower alkylsulfonyl; aryl; a 5- or 6-membered heterocyclic group; oxo; or oxide;
X is \u2014O\u2014, \u2014NR1\u2014 (wherein R1 is hydrogen, optionally substituted lower alkyl, lower alkenyl or lower alkylcarbonyl) or \u2014S(O)-p-wherein p is an integer of 0 to 2;
Y is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted lower alkoxycarbonyl, optionally substituted sulfamoyl, optionally substituted amino, optionally substituted aryl, pyrrole, imidazole, pyrazole, pyridine, pyridazine, pyrimidine, pyrazine, triazole, triazine, isoxazole, oxazole, oxadiazole, isothiazole, thiazole, thiadiazole, furan, thiophene, tetrahydropyran, dihydropyridine, dihydropyridazine, dihydropyrazine, dioxane, oxathiolane, thiane, pyrrolidine, pyrroline, imidazolidine, imidazoline, pyrazolidine, pyrazoline, piperidine, or morpholine;
R1 and Y taken together may form \u2014(CH2)m\u2014, \u2014(CH2)2\u2014T\u2014(CH2)2\u2014 wherein T is O, S or NR\u2032, \u2014CR\u2032\u2550CH\u2014CH\u2550CR\u2032\u2014, \u2014CH\u2550N\u2014CH\u2550CH\u2014, \u2014N\u2550CH\u2014N\u2550CH\u2014, C (\u2550O)\u2014(CH2)r-, \u2014C (\u2550O)\u2014NR\u2032\u2014(CH2)r- or \u2014C(\u2550O)\u2014NR\u2032\u2014N\u2550CH\u2014 wherein m is 4 or 5, r is 2 or 3 and R\u2032 is hydrogen, lower alkyl or lower alkenyl;
Y may be halogen when X is \u2014NR1\u2014 and
Y may be optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl when X is \u2014O\u2014 or \u2014NR1\u2014;
both V1 and V2 are single bonds or one of V1 and V2 is a single bond and the other is \u2014O\u2014, \u2014NH\u2014, \u2014OCH2\u2014, \u2014CH2O\u2014, \u2014CH\u2550CH\u2014, \u2014C\u2261C\u2014, \u2014CH(OR2)\u2014 wherein R2 is hydrogen or lower alkyl, \u2014CO\u2014, \u2014NHCHR \u2014 or \u2014CHR3NH\u2014 wherein R3 is hydrogen or hydroxy, or a prodrug, pharmaceutically acceptable salt or solvate thereof.
14. A method for inhibiting the differentiation from Th0 cells to Th2 cells comprising administering to a patient in need thereof a compound represented by Formula (Ib):
wherein ring C is an optionally substituted
and the pyridine ring may be optionally substituted, each of R4, R5, R6, R7, R8, R9, R10, and R11 is independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, carboxy or lower alkoxycarbonyl;
each of X1 and X2 is independently \u2014O\u2014, \u2014CH2\u2014 or \u2014NH\u2014;
each of Y1 and Y2 is independently optionally substituted lower alkyl, optionally substituted arylalkyl or optionally substituted lower alkenyl, or a prodrug, pharmaceutically acceptable salt or solvate thereof.
15. A method for treating graft immune diseases (chronic GVHD), ulcerative colitis, systemic lupus erythematodes, myasthenia gravis, systemic progressive scleroderma, rheumatoid arthritis, interstitial cystitis, Hashimoto’s diseases, Basedow’s diseases, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, Goodpasture’s syndrome, atrophic gastritis, pernicious anemia, Addison diseases, pemphigus, pemphigoid, lenticular uveitis, sympathetic ophthalmia, primary biliary cirrhosis, active chronic hepatitis, Sjogren’s syndrome, multiple myositis, dermatomyositis, polyarteritis nodosa, rheumatic fever, glomerular nephritis, lupus nephritis, IgA nephtopathy, allergic encephalitis, atopic allergic diseases, bronchial asthma, airway inflammation, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, pollinosis, urticaria, food allergy, Omenn’s syndrome, vernal conjunctivitis or hypereosinophilic syndrome comprising inhibiting the differentiation from Th0 cells to Th2 cells by administering to a patient in need thereof a compound represented by Formula (Ib)
wherein ring C is an optionally substituted pyridine ring, each of R4, R5, R6, R7, R8, R9, R10, and R11 is independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, carboxy or lower alkoxycarbonyl;
each of X1 and X2 is independently \u2014O\u2014 or \u2014NH\u2014;
each of Y1 and Y2 is independently optionally substituted lower alkyl, optionally substituted arylalkyl or optionally substituted lower alkenyl,
or a prodrug, pharmaceutically acceptable salt or solvate thereof.
16. A method for inhibiting the differentiation from Th0 cells to Th2 cells comprising administering to a patient in need thereof a compound represented by Formula (Ib):
wherein ring C is an optionally substituted pyridine ring, each of R4, R5, R6, R7, R8, R9, R10, R11, and R11 is independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkoxy, carboxy or lower alkoxycarbonyl;
each of X1 and X2 is independently \u2014O\u2014 or \u2014NH\u2014;
each of Y1 and Y2 is independently optionally substituted lower alkyl, optionally substituted arylalkyl or optionally substituted lower alkenyl,
or a prodrug, pharmaceutically acceptable salt or solvate thereof.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of connecting an emergency caller with an emergency response center, comprising:
establishing an emergency call conference;
adding said emergency caller to said established emergency call conference; and
adding said emergency response center to said emergency call conference;
wherein said emergency call is established after said emergency caller and said emergency response center are both added to said emergency call conference.
2. The method of connecting an emergency caller with an emergency response center according to claim 1, further comprising:
adding a third party to said emergency call conference;
3. The method of connecting an emergency caller with an emergency response center according to claim 1, wherein:
at least three parties are present in said emergency call conference at least at a beginning of said emergency call.
4. The method of connecting an emergency caller with an emergency response center according to claim 1, wherein said emergency response center comprises:
a public safety access point (PSAP).
5. The method of connecting an emergency caller with an emergency response center according to claim 2, wherein said third party comprises:
a police dispatcher.
6. The method of connecting an emergency caller with an emergency response center according to claim 2, wherein said third party comprises:
a fire department.
7. The method of connecting an emergency caller with an emergency response center according to claim 2, wherein said third party comprises:
an ambulance company.
8. The method of connecting an emergency caller with an emergency response center according to claim 1, wherein:
said emergency caller is added to said emergency call conference after said emergency response center is added to said emergency call conference.
9. The method of connecting an emergency caller with an emergency response center according to claim 1, wherein:
said emergency response center is added to said emergency call conference after said emergency caller is added to said emergency call conference.
10. Apparatus for connecting an emergency caller with an emergency response center, comprising:
means for establishing an emergency call conference;
means for adding said emergency caller to said established emergency call conference; and
means for adding said emergency response center to said emergency call conference;
wherein said emergency call is established after said emergency caller and said emergency response center are both added to said emergency call conference.
11. Apparatus for connecting an emergency caller with an emergency response center according to claim 10, further comprising:
means for adding a third party to said emergency call conference;
12. The apparatus for connecting an emergency caller with an emergency response center according to claim 10, wherein:
at least three parties are present in said emergency call conference at least at a beginning of said emergency call.
13. The apparatus for connecting an emergency caller with an emergency response center according to claim 10, wherein said emergency response center comprises:
a public safety access point (PSAP).
14. The apparatus for connecting an emergency caller with an emergency response center according to claim 11, wherein said third party comprises:
a police dispatcher.
15. The apparatus for connecting an emergency caller with an emergency response center according to claim 11, wherein said third party comprises:
a fire department.
16. The apparatus for connecting an emergency caller with an emergency response center according to claim 11, wherein said third party comprises:
an ambulance company.